HMA / EMA Task Force on the Availability of Authorised Medicines for Human and Veterinary Use (2016-2024)

Data access to medicinal products for human use - Chapter 5 Annex A: Product data elements accessible by stakeholder group

Good practice guidance for communication to the public on medicines’ availability issues

Medicine shortages and availability issues: guidance for regulators

Guidance on the procedural aspects for the consultation to the European Medicines Agency by a notified body on companion diagnostics - Revision 1

Questions & answers - Practical arrangements on the companion diagnostics consultation procedure to the European Medicines Agency by notified bodies

EMA procedural advice for medicinal products intended exclusively for markets outside the European Union in the context of co-operation with the World Health Organisation (WHO)

Pre-submission request form for a EMA procedure prior to the submission of a marketing authorisation application or Article 58 Application

EMA recommendation on the procedural aspects and dossier requirements for the consultation of the EMA by a notified body on an ancillary medicinal substance or an ancillary human blood derivative incorporated in a medical device - Revision 2

Quarterly system demo - Q4 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 12 December 2024, 09:00 (CET) to 12 December 2024, 12:00 (CET)